By Fineline Cube The seventh batch of China’s state‑organized centralized volume‑based procurement (VBP) of medical consumables opened bids in Tianjin and produced the selected results, covering 23 types of digestive intervention medical consumables. A total of 156 companies submitted bids for 558 products, and 517 products from 148 companies were selected, with mainstream products in clinical use generally being selected.
Policy Snapshot
| Item | Detail |
|---|---|
| Program | Seventh batch, state‑organized centralized volume‑based procurement (VBP) of medical consumables |
| Bid Opening Venue | Tianjin, China |
| Category Covered | Digestive intervention medical consumables — 23 product types |
| Bids Submitted | 156 companies, 558 products |
| Selected Results | 517 products from 148 companies |
| Selection Rate | ~92.7 % of bid products selected |
| Clinical Continuity | Mainstream products in clinical use generally selected |
| Event Date | 10 Sep 2026 |
Sector Focus – Digestive Intervention Medical Consumables
- Clinical Applications: Primarily used in endoscopic surgical treatment of digestive tract diseases, covering treatment scenarios such as biliary and pancreatic stones, digestive tract polyps and tumors, and digestive tract bleeding.
- Usage Profile: Characterized by large clinical volumes, many product models, and highly variable usage across different surgeries — a complex procurement category requiring careful specification design.
- Cost Impact: Following centralized procurement, the overall cost burden of digestive intervention treatment will be reduced, easing pressure on patients, payers and hospitals alike.
Procurement Results – Key Figures
| Metric | Value |
|---|---|
| Product categories procured | 23 |
| Companies bidding | 156 |
| Products bid | 558 |
| Products selected | 517 |
| Companies with selections | 148 |
| Average price reduction | Not disclosed in announcement |
| Procurement volume commitments | Not disclosed in announcement |
Market Impact & Outlook
- Continued VBP Expansion: The seventh consumables batch extends China’s centralized procurement campaign deeper into high‑value medical devices, following prior rounds that reshaped categories from coronary stents to orthopedic implants — signaling sustained policy momentum toward volume‑for‑price normalization across the device sector.
- Price Compression vs. Supply Stability: With mainstream clinical products generally selected and a ~92.7 % product selection rate, this round appears calibrated to balance cost reduction with continuity of hospital supply — mitigating the disruption risks seen in earlier device VBP cycles.
- Industry Consolidation Pressure: For the 148 selected companies, guaranteed hospital access comes at negotiated price concessions; manufacturers outside the winning group face shrinking share in China’s digestive intervention consumables market, likely accelerating consolidation among domestic device makers.
- Patient Access Dividend: Reduced consumables costs should lower out‑of‑pocket spending for common endoscopic procedures — from stone extraction to polypectomy and hemostasis — supporting higher procedure volumes under China’s DRG/DIP payment reforms; implementation timelines and contract volumes were not disclosed.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding the implementation of the seventh national VBP batch, including procurement volumes, contract execution and resulting price reductions for digestive intervention medical consumables. Actual results may differ materially due to risks including regional implementation schedules, supply chain execution and market dynamics. Specific price reduction levels and volume commitments were not disclosed.-Fineline Info & Tech